新型疫苗：构建能引发抗肿瘤免疫的病毒。
The new vaccines: building viruses that elicit antitumor immunity.
作者信息
Restifo N P
机构信息
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
出版信息
Curr Opin Immunol. 1996 Oct;8(5):658-63. doi: 10.1016/s0952-7915(96)80082-3.
Abstract
Whereas cancer cells are poor immunogens, some viruses are capable of eliciting powerful and lifelong immunity. Recombinant viruses and plasmid DNA encoding tumor-associated antigens can elicit powerful and specific immune responses that can be enhanced by the use of cytokines and costimulatory molecules. These immune responses have destroyed growing tumor cells in experimental animal models. For the first time, immunotherapeutic strategies that employ recombinant viruses are being tested in clinical trials with cancer patients.
摘要
癌细胞是弱免疫原，而一些病毒能够引发强大且持久的免疫反应。编码肿瘤相关抗原的重组病毒和质粒DNA可引发强大而特异的免疫反应，利用细胞因子和共刺激分子可增强这些反应。在实验动物模型中，这些免疫反应已摧毁了正在生长的肿瘤细胞。首次采用重组病毒的免疫治疗策略正在癌症患者的临床试验中进行测试。
相似文献
1
The new vaccines: building viruses that elicit antitumor immunity.
Curr Opin Immunol. 1996 Oct;8(5):658-63. doi: 10.1016/s0952-7915(96)80082-3.
2
3
Viral vectors for gene transfer into antigen presenting cells.
Curr Opin Mol Ther. 1999 Oct;1(5):558-64.
4
Antitumor vaccination: where we stand.
Haematologica. 2000 Nov;85(11):1172-206.
5
Strategies for immunotherapy of cancer.
Adv Immunol. 2000;75:235-82. doi: 10.1016/s0065-2776(00)75006-1.
6
Vaccine therapy of established tumors in the absence of autoimmunity.
Clin Cancer Res. 2003 May;9(5):1837-49.
7
DNA tumor vaccines.
Arch Immunol Ther Exp (Warsz). 2001;49(1):1-11.
8
Recombinant viruses as a tool for therapeutic vaccination against human cancers.
Immunol Lett. 2000 Sep 15;74(1):11-25. doi: 10.1016/s0165-2478(00)00244-3.
9
Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
Curr Opin Mol Ther. 1999 Aug;1(4):471-9.
10
Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue.
J Immunol. 2000 Jan 15;164(2):1125-31. doi: 10.4049/jimmunol.164.2.1125.
引用本文的文献
1
Influence of tumors on protective anti-tumor immunity and the effects of irradiation.
Front Oncol. 2013 Feb 1;3:14. doi: 10.3389/fonc.2013.00014. eCollection 2013.
2
Immunochemical termination of self-tolerance.
Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11276-80. doi: 10.1073/pnas.0804157105. Epub 2008 Aug 6.
3
Molecular cancer vaccines: Tumor therapy using antigen-specific immunizations.
Pathol Oncol Res. 1997 Sep;3(3):164-76. doi: 10.1007/BF02899917.
4
Escape from immunotherapy: possible mechanisms that influence tumor regression/progression.
Cancer Immunol Immunother. 2004 Oct;53(10):844-54. doi: 10.1007/s00262-004-0540-x. Epub 2004 Jun 10.
5
Cancer vaccines: progress reveals new complexities.
J Clin Invest. 2002 Aug;110(3):289-94. doi: 10.1172/JCI16216.
6
Creating therapeutic cancer vaccines: notes from the battlefield.
Trends Immunol. 2001 Jan;22(1):5-7. doi: 10.1016/s1471-4906(00)01793-2.
7
Challenges to the development of antigen-specific breast cancer vaccines.
Breast Cancer Res. 2001;3(2):95-8. doi: 10.1186/bcr278. Epub 2001 Jan 11.
8
Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases.
J Virol. 2000 Oct;74(19):9197-205. doi: 10.1128/jvi.74.19.9197-9205.2000.
9
The promise of nucleic acid vaccines.
Gene Ther. 2000 Jan;7(2):89-92. doi: 10.1038/sj.gt.3301117.
10
Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen.
J Immunol. 2000 Jan 15;164(2):562-5. doi: 10.4049/jimmunol.164.2.562.
本文引用的文献
1
Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model.
Vaccine. 1997 Mar;15(4):387-94. doi: 10.1016/s0264-410x(96)00195-8.
2
Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100.
J Immunother. 1997 Jan;20(1):15-25. doi: 10.1097/00002371-199701000-00002.
3
Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
J Immunother Emphasis Tumor Immunol. 1996 Jan;19(1):81-4.
4
The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product.
Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9730-5. doi: 10.1073/pnas.93.18.9730.
5
Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen.
J Immunother Emphasis Tumor Immunol. 1995 Oct;18(3):139-46. doi: 10.1097/00002371-199510000-00001.
6
Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines.
Cancer Res. 1996 Jun 15;56(12):2832-6.
7
IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.
J Immunol. 1996 May 1;156(9):3357-65.
8
Induction of antitumor immunity using bone marrow-generated dendritic cells.
J Immunol. 1996 Apr 15;156(8):2918-26.
9
Mutant ras epitopes as targets for cancer vaccines.
Semin Oncol. 1996 Feb;23(1):118-34.
10
Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases.
J Immunol. 1996 Jan 1;156(1):238-45.
Zotero 插件